NCT01616108 - Bupivacaine Injection of Eye Muscles to Treat Strabismus | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2020

Conditions

StrabismusEsotropiaExotropiaGraves DiseasePtosis, Eyelid

Interventions

DRUG

Bupivacaine

Differences in concentration from 0.75% to 3.0% are compared. Differences in volume for 1.0 mL to 3.0 mL are compared. Differences in compounding with addition of epinephrine will be used and compared to plain bupivacaine.

Trial Locations (1)

94109

RECRUITING

Strabismus Research Foundation, San Francisco